Drittlinientherapie mit Gefitinib beim nicht-kleinzelligen Bronchialkarzinom
| Autor: | U. Haffner, B. Spahlinger, D. Geiger, G. M. Dietrich, H. Lahm, J. R. Fischer |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology medicine.medical_specialty Modality (human–computer interaction) business.industry medicine.medical_treatment Translational research medicine.disease respiratory tract diseases Targeted therapy Gefitinib Internal medicine medicine business Lung cancer Selection (genetic algorithm) medicine.drug |
| Zdroj: | Pneumologie. 59:321-327 |
| ISSN: | 1438-8790 0934-8387 |
| DOI: | 10.1055/s-2004-830240 |
| Popis: | The EGFR-inhibition via tyrosine-kinase-inhibitor gefitinib (Iressa) constitutes a new way to treat non-small-cell lung cancer. Recent research results enable us to better understand the basics of molecular targeted therapy (MTT). These results are helpful to re-interpret the clinical results obtained so far for gefitinib and to consider for the first time in a predictive manner factors for the selection of patients suitable for therapy. Three case reports are presented in this paper which illustrate that -- with view to the results from translational research -- the use of gefitinib offers an efficient new therapeutic modality for the treatment of chemotherapy-resistant non-small-cell lung cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|